Skip to Content
Merck
  • Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.

Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.

Bioorganic & medicinal chemistry (2010-02-27)
Francisco J Prado-Prado, Xerardo García-Mera, Humberto González-Díaz
ABSTRACT

There are many of pathogen parasite species with different susceptibility profile to antiparasitic drugs. Unfortunately, almost QSAR models predict the biological activity of drugs against only one parasite species. Consequently, predicting the probability with which a drug is active against different species with a single unify model is a goal of the major importance. In so doing, we use Markov Chains theory to calculate new multi-target spectral moments to fit a QSAR model that predict by the first time a mt-QSAR model for 500 drugs tested in the literature against 16 parasite species and other 207 drugs no tested in the literature using spectral moments. The data was processed by linear discriminant analysis (LDA) classifying drugs as active or non-active against the different tested parasite species. The model correctly classifies 311 out of 358 active compounds (86.9%) and 2328 out of 2577 non-active compounds (90.3%) in training series. Overall training performance was 89.9%. Validation of the model was carried out by means of external predicting series. In these series the model classified correctly 157 out 190, 82.6% of antiparasitic compounds and 1151 out of 1277 non-active compounds (90.1%). Overall predictability performance was 89.2%. In addition we developed four types of non Linear Artificial neural networks (ANN) and we compared with the mt-QSAR model. The improved ANN model had an overall training performance was 87%. The present work report the first attempts to calculate within a unify framework probabilities of antiparasitic action of drugs against different parasite species based on spectral moment analysis.

MATERIALS
Product Number
Brand
Product Description

Supelco
Salbutamol, VETRANAL®, analytical standard
Supelco
Ursolic acid, analytical standard
Sigma-Aldrich
Estradiol, meets USP testing specifications
Sigma-Aldrich
DL-Aminoglutethimide
Sigma-Aldrich
Betamethasone, ≥98%
Sigma-Aldrich
β-Estradiol, ≥98%
Supelco
Codeine monohydrate, analytical standard
Sigma-Aldrich
Hydrochlorothiazide, meets USP testing specifications
Sigma-Aldrich
Ursolic acid, ≥90%
Sigma-Aldrich
Ketoprofen, ≥98% (TLC)
Sigma-Aldrich
Valproic acid sodium salt, 98%
Supelco
Tolbutamide, analytical standard
Sigma-Aldrich
Alprazolam
Sigma-Aldrich
Terfenadine
Sigma-Aldrich
Naproxen, meets USP testing specifications
Sigma-Aldrich
Digitoxin, ≥92% (HPLC), powder
Sigma-Aldrich
Salbutamol
Sigma-Aldrich
Diazepam
Sigma-Aldrich
Acetaminophen, analytical standard
Sigma-Aldrich
Acetaminophen, BioXtra, ≥99.0%
Sigma-Aldrich
Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder
Sigma-Aldrich
Furosemide
Sigma-Aldrich
Hydroxyurea, 98%, powder
Sigma-Aldrich
Hydrochlorothiazide, crystalline
Sigma-Aldrich
Hexadecyltrimethylammonium bromide, ≥96.0% (AT)
Sigma-Aldrich
Hexadecyltrimethylammonium bromide, BioUltra, for molecular biology, ≥99.0% (AT)
Supelco
Hexadecyltrimethylammonium bromide, suitable for ion pair chromatography, LiChropur
Supelco
Dexamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Hexadecyltrimethylammonium bromide, for molecular biology, ≥99%
Sigma-Aldrich
Hexadecyltrimethylammonium bromide, ≥98%